Table II.
Preoperative levels of urinary DiAcSpm, serum CEA and CA19-9 in patients with colorectal cancer.
| TNM stage | No. of cases | Urinary DiAcSpm (nmol/g·Cre) | Serum CEA (ng/ml) | Serum CA19-9 (U/ml) |
|---|---|---|---|---|
| 0+I | 19 | 258.6±101.1 | 2.0±1.2 | 60.3±194.9 |
| II | 32 | 625.8±1204.3 | 6.1±11.1 | 19.7±20.3 |
| III | 39 | 367.9±548.0 | 14.2±54.1 | 25.2±45.0 |
| IV | 23 | 1935.7±2412.9a | 45.2±79.6a | 1290.4±4850.2 |
| Total | 113 | 742.0±1426.0 | 16.2±50.1 | 287.1±2210.8 |
The urinary DiAcSpm levels in patients with stage IV disease were significantly elevated compared with those in patients with stage 0+I, II or III disease. Similarly, the serum CEA levels in patients with stage IV disease were significantly elevated compared with those in the patients with stage 0+I or II disease.
a
p< 0.05.
DiAcSpm, N1,N12-diacetylspermine; CEA, carcinoembryonic antigen; CA19-9, cancer antigen 19-9; TNM, Tumor-Node-Metastasis.